Skip to Content

Join the 'Hypogonadism' group to help and get support from people like you.

Hypogonadism News

TV Ads Help Drive Testosterone Supplement Sales

Posted 21 Mar 2017 by Drugs.com

TUESDAY, March 21, 2017 – TV ads have helped spur a boom in testosterone treatments, convincing many men that they need hormone replacement therapy, a new study suggests. In places where testosterone therapy ads ran, researchers discovered increases in testing for low T, initiation of testosterone replacement in new patients, and testosterone treatment without proper testing to see if hormone levels were abnormally low. "We found that each advertisement aired was associated with new use, new testing and new use without recent baseline tests," said lead author J. Bradley Layton, a research assistant professor of epidemiology with the University of North Carolina's Gillings School of Global Public Health. Testosterone replacement therapy experienced a boom in recent years, with the number of patients leaping from 1.3 million in 2009 to 2.3 million in 2013, according to the U.S. Food and ... Read more

Related support groups: Erectile Dysfunction, Testosterone, AndroGel, Testim, Axiron, Androderm, Hypogonadism - Male, Depo-Testosterone, Fortesta, Testopel, Oligospermia, Testopel Pellets, Hypogonadism, Testim 5 g/packet, Delatestryl, FIRST-Testosterone, Striant, AndroGel 1.25 g/actuation, Everone, Estradiol/Testosterone

FDA Approves Aveed (testosterone undecanoate) Injectable Testosterone Replacement Therapy

Posted 6 Mar 2014 by Drugs.com

DUBLIN, March 6, 2014 /PRNewswire/ – Endo International plc announced today that its operating company Endo Pharmaceuticals Inc. received U.S. Food and Drug Administration (FDA) approval of Aveed (testosterone undecanoate) injection for the treatment of adult men with hypogonadism (commonly known as Low-T) that is associated with a deficiency or absence of the male hormone testosterone. Aveed is a new prescription medicine indicated to produce serum testosterone levels in the normal range by administration of a single 3-mL (750 mg) intramuscular injection given once at initiation of therapy, at 4 weeks, and then every 10 weeks thereafter. It is expected to be available in early March. "Today's FDA approval of Aveed is a significant milestone for Endo. Aveed expands our branded portfolio of men's health products and highlights our passion and commitment to providing high quality ... Read more

Related support groups: Testosterone, Hypogonadism - Male, Hypogonadism, Low T

Ask a Question

Further Information

Related Condition Support Groups

Hypogonadism - Male